Claims

- A method for making a water insoluble
- 2 biocompatible composition, said method comprising combining,
- 3 in an aqueous mixture, a polyanionic polysaccharide, a
- 4 nucleophile, and an activating agent under conditions
- 5 sufficient to form said composition.
- 6 2. The method of claim 1 wherein two or more
- 7 polyanionic polysaccharides are employed.
- 3. The method of claim 1 or 2 wherein said
- 9 polyanionic polysaccharides are chosen from the group
- 10 consisting of carboxymethyl cellulose, carboxymethyl
- 11 amylose, hyaluronic acid, chondroitin-6-sulfate, dermatin
- 12 sulfate, heparin, and heparin sulfate.
- 13 4. The method of claim 1 wherein said polyanionic
- 14 polysaccharide is hyaluronic acid.
- 15 5. The method of claim 1 wherein said polyanionic
- 16 polysaccharide is carboxymethyl cellulose.
- 17 6. The method of claim 1 wherein said polyanionic
- 18 polysaccharide is carboxymethyl amylose.
- 7. The method of claim 2 wherein two of said
- 20 polyanionic polysaccharides are hyaluronic acid and
- 21 carboxymethyl cellulose.
- 22 8. The method of claim 1 wherein said activating
- 23 agent is chosen from the group consisting of benzotriazole-
- 24 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate,
- 25 O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium

- 26 hexafluorophosphate, bromotris(dimethylamino)phosphonium
- 27 hexafluorophosphate, bromotris(pyrrolidinyl)phosphonium
- 28 hexafluorophosphate and the corresponding halide salts
- 29 thereof.
- 30 9. The method of claim 1 wherein said polyanionic
- 31 polysaccharide are present in a concentration of 0.0002 -
- 32 0.1M.
- 33 10. The method of claim 9 wherein said polyanionic
- 34 polysaccharide is present in a concentration of 0.0005 -
- 35 0.02M.
- 36 11. The method of claim 1 wherein said method is
- 37 carried out at a pH 3.5 8.0.
- 38 12. The method of claim 1 wherein the stoichiometry
- 39 of said activating agent to said polysaccharide is at least
- 40 0.1 molar equivalent of said activating agent per molar
- 41 equivalent of said polyanionic polysaccharide.
- 42 13. The method of claim 1 wherein said nucleophile
- 43 is chosen from the group consisting of an amino acid amide,
- 44 a monofunctional amine, an amino acid ester, an amino
- 45 alcohol, an amino thiol, an amino phenol, an amino catechol,
- 46 an amino acid, a salt of an amino acid, a peptide, and a
- 47 protein.
- 48 14. The method of claim 1 wherein the stoichiometry
- 49 of said polyanionic polysaccharide to said nucleophile is at
- 50 least 1 molar equivalent of nucleophile per molar equivalent
- 51 of polyanionic polysaccharide.

- 52 15. A method for making a water insoluble
- 53 biocompatible composition, said method comprising combining,
- in an aqueous mixture, one or more polyanionic
- 55 polysaccharides, a modifying compound, a nucleophile, and an
- 56 activating agent under conditions sufficient to form said
- 57 composition wherein said modifying compound causes the
- 58 formation of a new active carbonyl groups on said
- 59 polyanionic polysaccharide.
- 60 16. The method of claim 15 wherein two or more
- 61 polyanionic polysaccharides are employed.
- 62 17. The method of claim 15 or 16 wherein said
- 63 polyanionic polysaccharides are chosen from the group
- 64 consisting of carboxymethyl cellulose, carboxymethyl
- 65 amylose, hyaluronic acid, chondroitin-6-sulfate, dermatin
- 66 sulfate, heparin, and heparin sulfate.
- 67 18. The method of claim 15 wherein said polyanionic
- 68 polysaccharide is hyaluronic acid.
- 69 19. The method of claim 15 wherein said polyanionic
- 70 polysaccharide is carboxymethyl cellulose.
- 71 20. The method of claim 15 wherein said polyanionic
- 72 polysaccharide is carboxymethyl amylose.
- 73 21. The method of claim 16 wherein two of said
- 74 polyanionic polysaccharides are hyaluronic acid and carboxyl
- 75 methyl cellulose.
- 76 22. The method of claim 15 wherein said modifying
- 77 compound is chosen from the group consisting of

- 78 1-hydroxybenzotriazole hydrate, 1-hydroxybenzotriazole
- 79 monohydrate, N-hydroxysulfosuccinimide,
- 80 N-hydroxysuccinimide, 4-nitrophenol, 2-nitrophenol,
- 81 4-nitrothiophenol, 2-nitrothiophenol, pentachlorophenol,
- 82 pentafluorophenol, imidazole, tetrazole, and
- 83 4-dimethylaminopyridine.
- 84 23. The method of claim 15 wherein said activating
- 85 agent comprises a carbodiimide.
- 86 24. The method of claim 23 wherein said
- 87 carbodiimide comprises 1-ethyl-3-(3-dimethylaminopropyl)
- 88 carbodiimide, or 1-ethyl-3-(3-dimethylaminopropyl)
- 89 carbodiimide methiodide.
- 90 25. The method of claim 15 wherein said polyanionic
- 91 polysaccharide is present in a concentration of 0.0002 -
- 92 0.1M.
- 93 26. The method of claim 25 wherein said polyanionic
- 94 polysaccharide is present in a concentration of 0.0005 to
- 95 0.02M.
- 96 27. The method of claim 15 wherein said method is
- 97 carried out at a pH 3.5 8.0.
- 98 28. The method of claim 15 wherein the
- 99 stoichiometry of said polyanionic polysaccharide to said
- 100 activating agent is at least 0.1 molar equivalent of said
- 101 activating agent per molar equivalent of said polyanionic
- 102 polysaccharide.

103 29. The method of claim 15 wherein the 104 stoichiometry of said modifying agent to said activating 105 agent is at least 1 molar equivalent of said modifying 106 compound per molar equivalent of said activating agent.

Ann the four thus and the form

- 30. The method of claim 15 wherein said nucleophile is chosen from the group consisting of an amino acid amide, a monofunctional amine, an amino acid ester, an amino alcohol, an amino thiol, an amino phenol, an amino catechol, an amino acid, a salt of an amino acid, a peptide, and a protein.
- 31. A water insoluble composition prepared according to the method of claim 1, 2, 15 or 16.
- 115 32. The composition of claim 31 wherein said 116 composition is in the form of a gel.
- 117 33. The composition of claim 31 wherein said 118 composition is in the form of fibers.
- 119 34. The composition of claim 31 wherein said 120 composition is in the form of a membrane.
- 35. The composition of claim 31 wherein said composition is in the form of a foam.
- 123 36. The composition of claim 31 wherein said 124 composition is in the form of an adhesion prevention 125 composition.

- 37. The composition of claim 31, further comprising a pharmaceutically active substance dispersed within said
- 128 composition.

4, [

<u>ļ</u>.

- 129 38. The composition of claim 37 wherein said
- 130 pharmaceutically active substance is chosen from the group
- 131 consisting of proteins, growth factors, enzymes, drugs,
- 132 biopolymers, and biologically compatible synthetic polymers.
- 133 39. A water insoluble composition comprising the
- 134 reaction product of a polyanionic polysaccharide, a
- 135 nucleophile, and an activating agent.
- 136 40. A water insoluble composition comprising the
 - 137 reaction product of two or more polyanionic polysaccharides,
- 138 a nucleophile, and an activating agent.
 - 139 41. The water insoluble composition of claim 39 or
 - 140 40 wherein said activating agent is chosen from the group
 - 141 consisting of benzotriazole-1-yloxytris(dimethylamino)-
 - 142 phosphonium hexafluorophosphate, O-benzotriazole-1-yl-
 - 143 N, N, N', N'-tetramethyluronium hexafluorophosphate,
 - 144 bromotris(dimethylamino)phosphonium hexafluorophosphate,
 - 145 bromotris(pyrrolidinyl)phosphonium hexafluorophosphate and
 - 146 the corresponding halide salts thereof.
 - 147 42. A water insoluble composition comprising the
 - 148 reaction product of a polyanionic polysaccharide, a
 - 149 modifying compound, a nucleophile, and an activating agent.
 - 150 43. A water insoluble composition comprising the
 - 151 reaction or product of two or more polyanionic
 - 152 polysaccharides, a modiying compound, a nucleophile, and an
 - 153 activating agent.

- 154 44. The composition of claim 39, 40, 42 or 43
- 155 wherein said polyanionic polysaccharides are chosen from the
- 156 group consisting of carboxymethyl cellulose, carboxymethyl
- 157 amylose, hyaluronic acid, chondroitin-6-sulfate, dermatin
- 158 sulfate, heparin, and heparin sulfate.
- 159 45. The composition of claim 39 or 42 wherein said
- 160 polyanionic polysaccharide is hyaluronic acid.
- 161 46. The composition of claim 39 or 42 wherein said
- 162 polyanionic polysaccharide is carboxymethyl cellulose.
- 163 47. The composition of claim 39 or 42 wherein said
- 164 polyanionic polysaccharide is carboxymethyl amylose.
- 165 48. The composition of claim 40 or 43 wherein two
 - 166 of said polyanionic polysaccharides are hyaluronic acid and
- 167 carboxy methyl cellulose.

, , 4 , c ,

l.

169

- 168 49. The composition of claim 39, 40, 42 or 43
 - wherein said nucleophile is chosen from the group consisting
 - 170 of an amino acid amide, a monofunctional amine, an amino
 - 171 acid ester, an amino alcohol, an amino thiol, an amino
 - 172 phenol, an amino catechol, an amino acid, a salt of an amino
 - 173 acid, a peptide, and a protein.
 - 174 50. The composition of claim 42 or 43 wherein said
 - 175 modifying compound is chosen from the group consisting of
 - 176 1-hydroxybenzotriazole hydrate, 1-hydroxybenzotriazole
 - 177 monohydrate, N-hydroxysulfosuccinimide,
 - 178 N-hydroxysuccinimide, 4-nitrophenol, 2-nitrophenol,

- 4-nitrothiophenol, 2-nitrothiophenol, pentachlorophenol, 179
- pentafluorophenol, imidazole, tetrazole, and 180
- 4-dimethylaminopyridine. 181
- 182 51. The composition of claim 42 or 43 wherein said
- 183 activating agent comprises a carbodiimide.
- 184 The composition of claim 51 wherein said
- carbodiimide comprises 1-ethyl-3-(3-dimethylaminopropyl) 185
- 186 carbodiimide, or 1-ethyl-3-(3-dimethylaminopropyl)
- carbodiimide methiodide. 187

fil.

- 188 The composition of claims 39, 40, 42 or 43
 - 189 wherein said composition is in the form of a gel.
 - 190 The composition of claims 39, 40, 42 or 43 54.
- Ton And wherein said composition is in the form of fibers. 191
 - 192 The composition of claims 39, 40, 42 or 43
- 193 1 wherein said composition is in the form of a membrane.
- ij. 194 The composition of claims 39, 40, 42 or 43
- 195 wherein said composition is in the form of a foam.
 - 196 The composition of claims 39, 40, 42 or 43
 - 197 wherein said composition is in the form of an adhesion
 - prevention composition. 198
 - 199 58. The composition of claims 39, 40, 42 or 43.
 - 200 further comprising a pharmaceutically active substance
 - 201 dispersed within said composition.

| 202 | 59. The composition of claim 58 wherein said |
|-----|---|
| 203 | pharmaceutically active substance is chosen from the group |
| 204 | consisting of proteins, growth factors, enzymes, drugs, |
| 205 | biopolymers, and biologically compatible synthetic polymers |

organ spring piliter, in the property of the property of the piliter, property of the piliter, property of the piliter of the